Literature DB >> 12095490

Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated.

Richard S Legro1, Margrit Urbanek, Allen R Kunselman, Benjamin E Leiby, Andrea Dunaif.   

Abstract

OBJECTIVE: To determine whether self-selected women with polycystic ovary syndrome (PCOS) are abnormal compared with a control population.
DESIGN: Case-control.
SETTING: Support group meeting organized and initiated by patients. PATIENT(S): Forty-five self-selected women with PCOS and 80 control women. INTERVENTION(S): Self-selected women with PCOS at a peer support conference completed a questionnaire, had a brief physical, and gave a fasting blood sample. MAIN OUTCOME MEASURE(S): Historical, biometric, and assay results. RESULT(S): Sixty percent of the women attending the conference participated in the study. Most had been diagnosed with PCOS on the basis of ovarian morphology (35%). They were more likely to be nulliparous and have a history of oligomenorrhea (96%). They were hyperandrogenemic (significantly elevated testosterone and DHEAS levels) compared with control women. Self-selected women with PCOS displayed multiple metabolic abnormalities compared with control women, including elevations in blood pressure, waist-hip ratio, fasting insulin, fasting total cholesterol, and fasting low-density lipoprotein cholesterol levels, as well as a significant decrease in fasting glucose-insulin ratio and high-density lipoprotein cholesterol levels. CONCLUSION(S): Self-selected women with PCOS have reproductive and metabolic abnormalities. The majority of these women received inadequate treatment despite having risk factors for endometrial cancer, diabetes, and/or heart disease. Our study also suggests that women attending or participating in a PCOS support group are willing and likely to participate in clinical studies.

Entities:  

Mesh:

Year:  2002        PMID: 12095490     DOI: 10.1016/s0015-0282(02)03153-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

Review 1.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  miRNA Profiling Reveals miRNA-130b-3p Mediates DENND1A Variant 2 Expression and Androgen Biosynthesis.

Authors:  Jan M McAllister; Angela X Han; Bhavi P Modi; Maria E Teves; Grace R Mavodza; Zachary L Anderson; Tsaiwei Shen; Lane K Christenson; Kellie J Archer; Jerome F Strauss
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

Review 3.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

4.  Relationship of ovarian volume with mean platelet volume and lipid profile in patients with polycystic ovary syndrome.

Authors:  Nermin Köşüş; Aydin Köşüş; Nilgün Ö Turhan
Journal:  Exp Ther Med       Date:  2011-08-04       Impact factor: 2.447

5.  Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler; E Carmina
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

6.  The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women.

Authors:  T G Valderhaug; J K Hertel; N Nordstrand; P O Dale; D Hofsø; J Hjelmesæth
Journal:  Diabetol Metab Syndr       Date:  2015-05-21       Impact factor: 3.320

7.  Impact of dyslipidemia on the cumulative pregnancy outcomes after first ovarian stimulation.

Authors:  Xue Jiang; Xinle Lu; Mingshu Cai; Yu Liu; Yihong Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-09       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.